Loading data for RNA — first visit, this takes a few seconds.
Atrium Therapeutics, Inc. (RNA)
NasdaqGS: RNA
· 实时价格 · USD
10.35
-0.16 (-1.52%)
收盘价： Sep 10, 2026, 3:59 PM
股价、关键数字和最新消息，都在这一页。
Atrium Therapeutics, Inc.（RNA）股价、分析与数据
-1.52% (1D)
| 买价 | 10.37 |
| 市值 | 175M |
| 营收（TTM） | 35.8M |
| 净利润（TTM） | -66M |
| 0.00 | |
| -5.44 | |
| n/a | |
| -1.27 | |
| 市净率（TTM） | 0.81 |
| 市销率（TTM） | 4.87 |
| 财报日期 | May 11, 2026 |
| 卖价 | 13.2 |
| 成交量 | 421,601 |
| 20日均量 | 214,196 |
| 开盘价 | 10.44 |
| 前收盘价 | 10.51 |
| 日内区间 | 10.28 - 10.74 |
| 52周区间 | 10.28 - 16.77 |
| 分析师 | n/a |
| 目标价 | n/a |
| 分红 | n/a |
| 除息日 | n/a |
关于 RNA
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipe...
公司完整简介财报意外
Atrium Therapeutics 已于 Aug 13, 2026 发布季度财报：
- 营收为 $19.64M 低于预期 $0, ， Infinity% 同比增长.
- 每股收益为 -1.18 低于预期 -0.54, ， 2.48% 同比增长.
第 1 页，共 2 页